Stress ulcer prophylaxis in the intensive care unit trial: detailed statistical analysis plan.

Krag, M; Perner, A; Wetterslev, J; Lange, T; Wise, M P; Borthwick, M; Bendel, S; Pelosi, P; Keus, F; Guttormsen, A B; Schefold, Joerg C.; Meyhoff, T S; Marker, S; Møller, M H (2017). Stress ulcer prophylaxis in the intensive care unit trial: detailed statistical analysis plan. Acta anaesthesiologica Scandinavica, 61(7), pp. 859-868. Wiley-Blackwell 10.1111/aas.12917

[img] Text
2017 06 15 - Schefold_PubMed 28608496.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (176kB) | Request a copy

BACKGROUND In this statistical analysis plan, we aim to provide details of the pre-defined statistical analyses of the Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) trial. The aim of the SUP-ICU trial is to assess benefits and harms of stress ulcer prophylaxis with a proton pump inhibitor in adult patients in the intensive care unit (ICU). METHODS The SUP-ICU trial is an investigator-initiated, international, multicentre, randomised, blinded, parallel-group trial of intravenously pantoprazole 40 mg once daily vs. placebo in 3350 acutely ill adult ICU patients at risk of gastrointestinal bleeding. The primary outcome measure is 90-day mortality. Secondary outcomes include the proportion of patients with clinically important gastrointestinal bleeding, pneumonia, Clostridium difficile infection or myocardial ischaemia, days alive without life support, serious adverse reactions, 1-year mortality, and a health economic analysis. Two formal interim analyses will be performed. The statistical analyses will be conducted according to the outlined pre-defined statistical analysis plan. The primary analysis will be a logistic regression analysis adjusted for stratification variables comparing the two intervention groups in the intention-to-treat population. In a secondary analysis, we will additionally adjust the primary outcome for potential random differences in baseline characteristics. The conclusion will be based on the intention-to-treat population. CONCLUSION Stress ulcer prophylaxis is standard of care in ICUs worldwide, but has never been tested in large high-quality randomised placebo-controlled trials. The SUP-ICU trial will provide important high-quality data on the balance between the benefits and harms of stress ulcer prophylaxis in adult critically ill patients.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Intensive Care, Emergency Medicine and Anaesthesiology (DINA) > Clinic of Intensive Care

UniBE Contributor:

Schefold, Joerg C.

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0001-5172

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Mirella Aeberhard

Date Deposited:

10 Oct 2017 10:48

Last Modified:

10 Oct 2017 16:27

Publisher DOI:

10.1111/aas.12917

PubMed ID:

28608496

BORIS DOI:

10.7892/boris.101340

URI:

https://boris.unibe.ch/id/eprint/101340

Actions (login required)

Edit item Edit item
Provide Feedback